The International Glaucoma Association (IGA) advises Muslim glaucoma patients not to stop taking eye drop medication during Ramadan (Tuesday 15 May to Thursday 14 June) as stopping drops even for a short period of time can cause permanent loss of vision.

    Hospital reports and calls to the IGA helpline have indicated that some Muslims cease using their eye drops during Ramadan, believing that using the eye drops will break their fast. Even more worrying is that many of these patients then stop using the drops completely when they don’t perceive any change to their sight. This will not be apparent to the individual until significant sight loss has occurred.

    Glaucoma is a group of eye conditions in which the optic nerve is damaged, usually by excessive pressure within the eye. If left untreated, glaucoma can lead to serious loss of vision, with up to 40 per cent of sight being permanently lost before the effects are noticed by the individual.   Fortunately glaucoma is the most common cause of preventable blindness and for the majority of glaucoma patients, daily eye drops are a simple solution to control their condition and save their sight.

    Subhash Suthar, IGA Development Manager, comments: “We want to reassure the Muslim community that drops can be taken before dawn and after sunset (known as Suhoor and Iftar), when food and drink can be consumed. We also suggest that patients close the tear duct when taking eye drops (known as punctual occlusion) as this means that fluid stays in the eye and does not drain into the throat and so cannot be tasted. This is achieved by putting finger pressure at the corner of the eye next to the nose (punctual occlusion) immediately after instilling drops. It is distressing when patients realise through a follow up appointment at their ophthalmologist or optometrist that their vision has been damaged through stopping drops. ”

    The IGA is working with the Muslim Council of Britain (MCB) to raise awareness of this issue.

    MCB’s Deputy Secretary General Dr Omer El-Hamdoon, has confirmed that all Islamic Schools Of Thought agree that taking eye drops does not invalidate the fast unless the eye drops reach the throat, which is unlikely. More so, Islam advocates that people take care of their bodies.

    IGA Advice for eye drops during Ramadan:

    1. Do not stop eye drops during Ramadan- all Schools of Thought support this
    2. If you are still doubtful, use morning drops at Suhoor and evening drops at Iftar
    3. Try practicing punctal occlusion following instillation of drops

    As National Glaucoma Awareness Week approaches (4-10 June) the IGA also advises anyone planning a summer holiday to make sure they take their eye drops with them, as some patients either forget to take their drops with them, or think it will be fine to stop taking them while away, which could lead to serious sight loss.

    The IGA works with all professionals involved in glaucoma management to educate about the need for good eye drop use and compliance. It helps to set up local patient support groups within hospitals and has some simple tips and films available on our website.

    For more information on the IGA call 01233 64 81 64 or log onto


    For further information please contact Annabel Hillary, 07884 430862, annabel@prwhenyouneedit.co.uk

    or Mary-Jane Greenhalgh, 07866 722051, maryjane@prwhenyouneedit.co.uk

    or Karen Brewer on: 01233 64 81 64 or email: K.Brewer@iga.org.uk or R.Kew@iga.org.uk

    About the International Glaucoma Association (Charity Registered in England & Wales no. 274681, in Scotland no. SC041550)

    1. The International Glaucoma Association (IGA) is the charity for people with glaucoma, with the mission to raise awareness of glaucoma, promote research related to early diagnosis and treatment, and to provide support to patients and all those who care for them. For more information, please visit:


    1. Set up in 1974, it is the oldest patient based glaucoma association in the world and it is a Charity Registered in Scotland, Northern Ireland, England & Wales.
    2. As part of its support services, it operates the IGA Sightline (helpline) and provides free information on any aspect of glaucoma.

    4. For more information about glaucoma, contact the International Glaucoma Association (IGA) Sightline on 01233 64 81 70 (Monday to Friday, 9.30am–5.00pm).

    Read more

  • High level Education Strategic Review consultation responses show support for new education approach

    The GOC has published some high level findings from its Education Strategic Review concepts and principles consultation. 

    The high level summary publication shows 97 per cent of respondents agreed with the development of new education standards for optometrists and dispensing opticians. 82 per cent agreed with embedding clinical experience progressively from the start of education programmes.

    Stakeholders also showed support for the GOC further informing its education requirements with its Standards for Practice for Optometrists and Dispensing Opticians, with 84 per cent in favour of embedding professionalism into education and training programmes. 

    GOC Chief Executive and Registrar, Vicky McDermott said: “We are delighted to have received many supportive responses to the consultation that will enable us to work at pace to develop our detailed proposals to equip future professionals with the skills, knowledge and behaviours needed to practise safely and competently in a changing sector.

    “We will make concerted progress in the coming months to transform these concepts into workable approaches for the future.”

    The GOC’s Education Strategic Review concepts and principles consultation ran from December 2017 to March 2018, comprised 21 questions and sought feedback on 11 concepts and principles. A total of 36 responses were received to the consultation, 26 from organisations and 10 from individuals.  

    The GOC has also commissioned a full independent analysis of the consultation feedback and will publish this separately. 

    To read the high level findings summary please visit: https://www.optical.org/en/Education/education-strategic-review/supplementary-reading.cfm


    Read more

  • The IGA professor is 17th on the list of 100 most influential people in ophthalmology

    #17 David (Ted) Garway-Heath

    David (Ted) Garway-Heath

    IGA Professor of Ophthalmology for Glaucoma and Allied Studies, Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK

    Ted’s research has yielded many new diagnostic and monitoring tools, including the Moorfields Motion Displacement Test that identifies the loss of peripheral vision; The Moorfields Regression Analysis, software that assists glaucoma diagnosis from scanning laser tomography images; and the Garway-Heath Map, which is used in research and clinical practice to map the correspondence between visual field and optic nerve head damage. He was chief investigator for the UK Glaucoma Treatment Study, the first placebo-controlled trial for the medical treatment of glaucoma with a visual field loss outcome. In his research, he aims to continue to improve glaucoma diagnostic techniques, clinical trial design and identify risk factors for glaucoma. He recognizes the importance of multidisciplinary collaboration for successful research and has long-term productive collaborations with statisticians, computer scientists and academics in other fields of medicine. Advancement of knowledge and scientific progress comes from bias-free dialogue with peers, mentees and mentors.

    Ted is fortunate enough to include amongst his mentors Roger Hitchings, with whom he undertook clinical and research fellowships, Joe Caprioli, with whom he did a research fellowship, and George Spaeth, mentor in turn to both Hitchings and Caprioli. As President of the European Glaucoma Society, his aims for the coming years are to increase patient participation in the Society, build the education resources, establish a common platform to measure care outcomes across Europe and strengthen ties with other national and international Glaucoma Societies.


    Read more

  • Moorfields appoints IGA trustee, Nick Strouthidis as its new medical director

    26 February 2018

    Source: Moorfields

    Moorfields Eye Hospital NHS Foundation Trust has appointed Nick Strouthidis to the post of  medical director. Currently a consultant ophthalmologist in Moorfields’ glaucoma service and the glaucoma service director, Nick has worked for the Trust since 2002.

    Nick began his career at Moorfields as a research fellow to the glaucoma research unit and completed most of his training at Moorfields as both a registrar and a clinical glaucoma fellow. His clinical interests cover all aspects of adult glaucoma, particularly new surgical treatments. Alongside corneal consultant colleague Mark Wilkins, he runs the UK’s first integrated clinic for patients undergoing keratoprostheses, a surgical procedure to replace a diseased cornea with an artificial cornea.

    Nick was appointed to this pivotal role following a rigorous recruitment process, involving external stakeholders.

    Nick Strouthidis said:
    “It is an honour to take on the role of medical director at Moorfields Eye Hospital NHS Foundation Trust, an organisation that has shaped my professional life. I will work hard with our incredible staff to ensure we succeed in delivering our five-year strategy to work with patients and partners to discover, develop and deliver the best eye care.”
    The search for a new medical director began in response to outgoing medical director Declan Flanagan stepping down after eight years to focus on his clinical practice. Declan will continue to serve as medical director until August, when Nick takes up the post. After that, Declan will remain with the trust as a consultant ophthalmologist in the medical retina service, where he specialises in the treatment of retinal diseases.

    David Probert, chief executive of Moorfields Hospital NHS Foundation Trust said:
    “I look forward to Nick joining the executive team at Moorfields and congratulate him on his appointment. I am incredibly grateful for Declan’s exceptional leadership throughout his time as medical director.”

    Declan Flanagan said: “Spending the past eight years as Moorfields’ medical director has been a privilege. I am proud that, despite growing demand for our services, our clinical outcomes continue to be among the best in the world.”

    Read more

  • IGA wins commendation at Ophthalmology Awards 2017

    The IGA together with Princess Alexander Eye Pavilion, NHS Lothian receives a commendation for a local patient-led support group for Scotland aimed at reaching out to patients to improve awareness of glaucoma in the community.

    ‘Glaucoma Support Edinburgh’ was formed by a group of patients to address several unmet needs as the NHS now believe patients should take responsibility for their own health, and a support group/forum where patients can build their knowledge is an aid to this goal. The initiative began by recruiting a small group of patients, representatives from the International Glaucoma Association (IGA) and glaucoma specialists from the Princess Alexandra Eye Pavilion, to form a project steering committee.

    Their aim was to establish a local patient-led support group for Scotland with its own identity, but affiliated to the IGA, with the aim of reaching out to patients and improve awareness of glaucoma in the community.

    A website was developed to provide patients with information on meetings and events which is now used as a local awareness/information site. The culture of ‘patients supporting patients’ has led to growth in the number of patients engaging with and accessing the support provided. The group has relieved pressure on the NHS services where there is little extra funding for patient education.

    Judges’ comments:
    “This entry showcased ‘excellent results’ and fulfils the unmet need that exists in some ophthalmology units. The judges found it interesting and demonstrated clear innovation by being patient led – overall it was a good use of patient support groups and patient ownership.”

    For more information about the 2017 winners, click here

    About the awards

    The Ophthalmology Honours recognise and celebrate the outstanding work being carried out by multi-disciplinary teams in ophthalmology throughout the UK. The awards identify exceptional initiatives that demonstrate clinical excellence and innovation in ophthalmology, and recognise exceptional individuals who improve the quality of care provided to patients and the patient experience. Funded and facilitated by Bayer, the awards are judged by a multi-disciplinary panel of experts in ophthalmology care and the decision-making process is wholly independent of Bayer.

    Read more

  • European Glaucoma Society

    Guess who’s going to be the next President?


    Our very own Professor for glaucoma, David (Ted) Garway-Heath will be taking the reins as the next President of the EGS from January 2018.

    Currently as Vice President, Ted’s work is focused on establishing outcomes to evaluate care quality across Europe, harmonizing ophthalmology training, and mentoring the younger generation of glaucoma specialists who will be taking the society forward.

    In addition to his clinical work, Ted leads research in visual assessment and imaging at the Biomedical Research Centre for Ophthalmology of the UK National Institute for Health Research (NIHR). He is also an NHIR Senior Investigator, a position awarded in recognition of his contribution to patient and people-based research.

    On his latest achievement, our professor said: "I will build on the current strong and innovative leadership in pursuit of the patient-focused EGS vision to promote the best possible well-being and minimal glaucoma-induced visual disability in individuals with glaucoma."

    Everyone here at the IGA wishes Ted all the best in his new role next year, and we’re sure he’ll be a great success!

    Read more

  • IGA trustee Professor Anthony King comments on new test to detect glaucoma

    "This is a potentially significant new test. It is novel in its application. There is no real comparable test available that looks at the eye in such a detailed way and it would certainly add to our current ability to evaluate patients with glaucoma. The researchers have shown that it appears to be safe and it can identify patients who have glaucoma and it is possibly predictive of patients who will have glaucoma progression so all of that is very positive for the future.

    "It is a very experimental paper and the way that the test is administered wouldn't be at all practical in the NHS. It's time consuming and involves an intravenous injection. Patients need to have pupils dilated and then there is a need to have scans so they would have to remain in the department for several hours, so it would be both time consuming for the patient and time consuming for the ophthalmology service. However it's likely that with future research these things could be refined significantly to hone it down to a more efficient delivery.

    There is no cure, but we can manage glaucoma to stop it progressing so this is a test that allows us to diagnose glaucoma at an earlier stage and also identify patients more likely to progress more quickly to implement treatments to stop it from progressing. Often one of the difficulties with glaucoma is that there are no early signs and people can have significant visual field loss before they are detected. As with most conditions the later that a condition is identified, the more difficult it becomes to treat it effectively. So many people will have glaucoma without being aware of it and they only become aware of it when they go to their optician for a routine evaluation and it is picked up then."

    The IGA believes that everyone should have an eye health check every two years and more regularly if recommended by a health professional.


    New eye test detects earliest signs of glaucoma

    A SIMPLE eye test could help solve the biggest global cause of irreversible blindness, glaucoma.

    In clinical trials, the pioneering diagnostic - developed by researchers at University College London (UCL) and the Western Eye Hospital - allowed doctors to see individual nerve cell death in the back of the eye.

    Glaucoma affects 60 million people in the world, with 1 in 10 suffering total sight loss in both eyes.

    Early detection means doctors can start treatments before sight loss begins. The test also has potential for early diagnosis of other degenerative neurological conditions, including Parkinson’s, Alzheimer’s and multiple sclerosis.

    Results of first clinical trials with glaucoma patients are published today (28/04/17) in the journal BRAIN.

    Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: “Detecting glaucoma early is vital as symptoms are not always obvious. Although detection has been improving, most patients have lost a third of vision by the time they are diagnosed. Now, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin. In the future, the test could also be used to diagnose other neurodegenerative diseases.”

    Loss of sight in patients with glaucoma is caused by the death of cells in the retina at the back of the eye. This cell death is called apoptosis.

    As with other neurodegenerative conditions, more and more nerve cells are lost as the disease progresses.

    Professor Philip Bloom, Chief Investigator at Western Eye Hospital, part of Imperial College Healthcare NHS Trust, added: “Treatment is much more successful when it is begun in early stages of the disease, when sight loss is minimal. Our developments mean we could diagnose patients 10 years earlier than was previously possible.”

    The technique developed is called DARC, which stands for detection of apoptosing retinal cells. It uses a specially developed fluorescent marker which attaches to cell proteins when injected into patients. Sick cells appear as white fluorescent spots during eye examination. UCL Business, the commercialisation company of UCL, holds the patents for the technology.

    The examination uses equipment used during routine hospital eye examinations. Researchers hope that eventually it may be possible for opticians to do the tests, enabling even earlier detection of the disease.

    The research is funded by Wellcome Trust.

    Bethan Hughes, from Wellcome’s Innovation team said: “This innovation has the potential to transform lives for those who suffer loss of sight through glaucoma, and offers hope of a breakthrough in early diagnosis of other neurodegenerative diseases. Loss of sight as you age is an incredibly difficult disability, impacting quality of life and independence.”

    Initial clinical trials were carried out on a small number of glaucoma patients and compared with tests on healthy people. The initial clinical trials established the safety of the test for patients.

    Further studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.


    Link to paper: The following link will go live at the time the embargo lifts: https://academic.oup.com/brain/article-lookup/doi/10.1093/brain/awx088
    For embargoed copies of the BRAIN paper and for media enquiries please contact Maggie Stratton: m.stratton@wellcome.ac.uk +44 (0)20 7611 8609/ +44 (0)787 211 2656
    For further information about DARC technology please contact Emma Alam: e.alam@uclb.com +44 (0)207 679 9000/ +44 (0)7896 058667
    About UCL Business

    UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. For further information, please visit: www.uclb.com Twitter: @UCL_Business

    About UCL (University College London)

    UCL was founded in 1826. We were the first English university established after Oxford and Cambridge, the first to open up university education to those previously excluded from it, and the first to provide systematic teaching of law, architecture and medicine. We are among the world's top universities, as reflected by performance in a range of international rankings and tables. UCL currently has over 38,000 students from 150 countries and over 12,000 staff. Our annual income is more than £1 billion. www.ucl.ac.uk | Follow us on Twitter @uclnews | Watch our YouTube channel YouTube.com/UCLTV

    About Imperial Hospitals NHS Trust/Western Eye Hospital

    Imperial College Healthcare NHS Trust is one of the largest hospital Trust’s in England, providing acute and specialist healthcare for a population of nearly two million people. The Trust has five hospitals – Charing Cross, Hammersmith, Queen Charlotte’s & Chelsea, St Mary’s and The Western Eye – as well as community services.

    The Western Eye Hospital is a specialist eye hospital in West London with a 24/7 accident and emergency department. The hospital’s facilities also include outpatients, inpatients, day case and inpatient surgery.

    About Wellcome

    Wellcome exists to improve health for everyone by helping great ideas to thrive. We’re a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate.

    Read more

  • Glaucoma support meeting in Buxton for patients and carers on 31 March

    A free information and support event for people affected by eye disease glaucoma, is being held in Buxton on Friday 31 March – all welcome.

    The International Glaucoma Association will be joining forces with glaucoma experts from Derbyshire Community Health Services NHS Foundation Trust for the support meeting in Buxton Methodist Church Hall, Chapel Street, SK17 6HX from 1.30pm until 3-30pm.

    Buxton-based glaucoma nurse Norma Ayres said: “Glaucoma is a leading cause of preventable blindness and we are keen to raise further awareness to help people most at risk and to offer support to those affected.”

    The International Glaucoma Association (IGA) is a charity which funds research to help understand this complex condition where the optic nerve in the eye is damaged.

    Glaucoma affects 1-2% of people in their 40s, and for people over 80 this may be as high as 15%. People are not usually aware they have this condition in the early stages. It is recommended that people over 40 have eye tests with an optician every two years. These are free if a family member has glaucoma.

    One of the current research projects supported by the IGA is to compare mitochondrial DNA damage in cells from samples of blood and eye tissue of people with glaucoma to assess if the eye tissue is more vulnerable to damage. This may lead to identifying patients whose optic nerve is more susceptible to disease and treating them earlier and more appropriately.


    The Glaucoma Research Foundation suggests that immediate family members of people with the most common type of glaucoma, Primary Open Angle Glaucoma, are four to nine times at higher risk of developing glaucoma than the rest of the population.

    Glaucoma is mainly painless, and sight loss is gradual, usually affecting peripheral vision first, which means it often goes unnoticed. Opticians can detect signs of glaucoma during sight tests and eye examinations.

    At the glaucoma support meeting Conrad Yuen, a consultant ophthalmologist from Stepping Hill Hospital, will explain different aspects of glaucoma and how it is treated. He will also answer questions.

    David Harris from the International Glaucoma Association (IGA) will talk about the work of the IGA and its research programmes.

    For more information contact Norma Ayres, specialist glaucoma nurse at Cavendish Hospital, Buxton, on 01298 212850.



    • Derbyshire Community Health Services NHS Foundation Trust cares for patients across a wide range of services, delivered from 133 sites including 11 community hospitals and 30 health centres across Derbyshire, with nearly 1.5 million patient contacts each year.
    • The Trust employs approximately 4,500 staff, making it one of the largest providers of specialist community health services in the country, serving a patient population of 1.1 million.
    • Derbyshire Community Health Services NHS Foundation Trust’s

    Vision:  To be the best provider of local healthcare and to be a great place to work. Values: To get the basics right, to act with compassion and respect, to make a difference, to value and develop teamwork, to value everyone's contribution to our service delivery and development.

    MEDIA CONTACT: Rebecca Beedie, tel 07717 714239 or email: r.beedie@nhs.net or Rob Steel, tel 07527 420221 or email: robertsteel1@nhs.net

    Ref No: DCHS/RB/539

    Read more

  • Specsavers and IGA partnership to raise glaucoma awareness

    17 February 2017

    Specsavers and the International Glaucoma Association (IGA) are joining up in a million pound health information campaign to raise awareness of glaucoma and encourage people to have regular eye examinations.

    Glaucoma – often described as the ‘silent thief of sight’ due to its gradual onset – causes damage to the optic nerve. It affects 600,000 in the UK and more than 64 million people worldwide making it the leading cause of irreversible blindness globally .

    The campaign begins by highlighting research findings that men are at greater risk of losing their sight than women because they ignore warning signs and do not seek medical attention. The research, which focused on glaucoma, was carried out by City University and showed that men are 16% more likely than women to suffer advanced vision loss on diagnosis of the condition.

    Timed to coincide with World Glaucoma Week , which runs from 12 to 18 March, the campaign will include TV and national press advertising, online activity and posters and health information in Specsavers’ 770 stores nationwide.

    Welcoming the partnership, Karen Osborn, CEO of the IGA, says: ‘Glaucoma is found in 2% of the UK’s population aged over 40 . Most of those people have a slow developing form of the condition and we estimate that half of all cases – that’s over 300,000 people – remain undiagnosed and are unaware that they are slowly losing their sight.

    ‘Research shows more men than women are expected to be in this group because they simply do not seek medical treatment as readily as women.

    ‘The health awareness campaign the IGA is working on with Specsavers will educate about the importance of regular eye examinations before significant sight is lost. Once sight is lost, it cannot be recovered..’

    The Specsavers IGA partnership follows a similar agreement between Specsavers and Royal National Institute of Blind People announced last August. The logos of all three organisations will appear at the end of the Specsavers TV ad which airs from Sunday onwards.

    Sally Harvey, Chief Executive of RNIB, says: ‘We welcome any initiative that encourages people to look after their eye health.

    ‘Regular eye tests and early detection on the high street, followed by timely intervention and management of eye health conditions, could help save your sight.’

    Doug Perkins, Co-founder of Specsavers and an optometrist for more than 50 years, is delighted by the partnerships with the IGA and RNIB.

    He says, ‘Working together with people who are so committed to eye health and do such amazing work is a real privilege. I am looking forward to a long and fruitful relationship with them.’

    Following Specsavers’ drive last year for all its optometrists to be Level 2 accredited in minor eye conditions, the focus has switched to glaucoma accreditation. By World Glaucoma Week, every Specsavers store will have at least one optometrist who has completed the WOPEC (Wales Optometry Postgraduate Education Centre) Level 1 glaucoma accreditation, reinforcing their skills in detecting glaucoma and monitoring the signs of its progression, with Level 2 set to be achieved by all optometrists by September.

    - ends -

    Image – Optometrist performs glaucoma assessment

    About the International Glaucoma Association:
    • The International Glaucoma Association (IGA) is the charity for people with glaucoma. Its mission is to raise awareness of glaucoma, promote research related to early diagnosis and treatment, and to provide support to patients and all those who care for them. For more information, please visit: www.glaucoma-association.com
    • Set up in 1974, it is the oldest patient based glaucoma association in the world and it is a registered charity in England and Wales, and also in Scotland
    • As part of its support services, the IGA operates the Sightline (telephone helpline) and provides free information on any aspect of glaucoma.
    • For more information about glaucoma, contact the International Glaucoma Association (IGA) Sightline on 01233 64 81 70 (Monday to Friday, 9.30am–5.00pm).
    • In England, Wales and Northern Ireland close relatives of people with glaucoma who are aged 40 plus can have a sight test and examination by an optometrist which is paid for by the NHS, and everyone aged 60 and over is entitled to free testing. In Scotland, the NHS will pay for glaucoma examinations offered by optometrists, regardless of age.

    Specsavers notes to editors:
    • Specsavers is a partnership of almost 2,000 locally-run businesses throughout the world -all committed to delivering high quality, affordable optical and hearing care in the communities they serve.
    • Each store is part-owned and managed by its own joint venture partners who are supported by key specialists in support offices.
    • More than 31 million customers used Specsavers in 2016 and the partnership had a turnover of more than £2bn.
    • More than one in three people who wear glasses in the UK buy them from Specsavers.
    • Specsavers is a champion of the National Health Service – of its 19.2m customers in the UK, 60% are from the NHS and the company is the largest provider of free NHS digital hearing aids.
    • Specsavers supports several UK charities and is in partnership with RNIB for a public awareness campaign to transform the nation’s eye health.

    About RNIB
    • Every 15 minutes, someone in the UK begins to lose their sight. We are RNIB (The Royal National Institute of Blind People) and we're here for everyone affected by sight loss – that's over 2 million people in the UK.

    Read more

  • Events for Visually Impaired Visitors January – March 2017


    vvvAll V&A events are accessible to blind or partially sighted visitors, and an accompanying friend or carer may claim free entry. We also offer concessionary entry to V&A exhibitions for blind or partially sighted visitors and free entry for up to 2 friends or carers.

    We hope your visit to the V&A will be easy and enjoyable. To arrange for specific support, please contact the V&A Contact Centre.

    If you would like to receive this newsletter via email in future, please email us at disability@vam.ac.uk.

    All events start from the Meeting Point, Grand Entrance.


    Glastonbury: Land and Legend (Descriptive Tour)

    Tuesday 17 January, 11.0012.00

    The Camera Exposed (Descriptive Tour)

    Thursday 16 February 2017, 11.00 – 12.00

    Exploration and Exploitation (Touch Tour)

    Wednesday 8 March 2017, 11.00 – 12.00

    Free, advanced booking essential

    To book: Call 020 7942 2211

    Fax 020 7942 2524

    Email: bookings.office@vam.ac.uk

    Read more

11-20 of 30